{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:06:39Z","timestamp":1775840799734,"version":"3.50.1"},"reference-count":56,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22k08501"],"award-info":[{"award-number":["22k08501"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CURED Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Whereas chimeric antigen receptor gene modified T (CAR-T) cell therapy has been clinically applied to malignant lymphomas and multiple myeloma, CAR-T cell therapy for solid tumors has so far not reached clinical application. Epithelial V-like antigen 1 (Eva1), transcribed from <jats:italic>myelin protein zero-like 2 (MPZL2),<\/jats:italic> is a small surface protein highly expressed on various tumor cells. We selected Eva1 as a novel solid tumor-target antigen because of its broad expression across various tumor types. The purpose of the present study is to develop and optimize CAR-T cells targeting Eva1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>We prepared various humanized single chain variable fragment sequences based on a mouse anti-human Eva1 monoclonal antibody. We constructed six humanized Eva1CAR-Ts and selected one that maintained specificity and good cellular proliferation after antigen stimulation. We further optimized the length of the extracellular spacer domain and the choice of the intracellular domain in vitro and in two different xenograft mouse models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We confirmed Eva1 expression on various tumor cell lines by flow cytometry and analysis of public database, but we also observed that normal monocytes weakly expressed Eva1. A combination of short spacer domain and 4-1BB or CD79A\/CD40 intracellular domain provided higher treatment efficacy both in vitro and in vivo. The cytokine release on autologous monocyte stimulation to Eva1CAR-T cells was comparable to that on autologous B cell stimulation to CD19CAR-T cells. Humanized Eva1CAR-T cells demonstrated excellent therapeutic efficacy by infusing a single dose of Eva1CAR-T cells (1\u00d710<jats:sup>6<\/jats:sup>) in both NCI-H1975 lung cancer and CFPAC-1 pancreatic cancer cell line grafted model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In summary, these data suggest that humanized Eva1CAR-T has promising therapeutic potential for the treatment of various Eva1-positive solid tumors. Regarding on-target\/off-tumor recognition, further detailed analyses of the Eva1CAR-T cell responses to normal tissues are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-009825","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:25:21Z","timestamp":1746667521000},"page":"e009825","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Development and optimization of Eva1 (<i>MPZL2<\/i>) targeting chimeric antigen receptor T cells"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9110-2579","authenticated-orcid":false,"given":"Masahide","family":"Osaki","sequence":"first","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-8046","authenticated-orcid":false,"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Hirano","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Iwasa","sequence":"additional","affiliation":[{"name":"CURED Inc, Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako C","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Center for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3128-1477","authenticated-orcid":false,"given":"Yutaka","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Center for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Sunagawa","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kokuryo","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Adachi","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-7909","authenticated-orcid":false,"given":"Ryo","family":"Hanajiri","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3840-7304","authenticated-orcid":false,"given":"Chie","family":"Sakanaka","sequence":"additional","affiliation":[{"name":"CURED Inc, Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Murata","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ebata","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2025100305301280000_13.5.e009825.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025100305301280000_13.5.e009825.2","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2025100305301280000_13.5.e009825.3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.38793","article-title":"Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action","volume":"4","author":"Olivier","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025100305301280000_13.5.e009825.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00723-4"},{"key":"2025100305301280000_13.5.e009825.5","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"2025100305301280000_13.5.e009825.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2"},{"key":"2025100305301280000_13.5.e009825.7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11809","article-title":"Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis","volume":"3","author":"Kok","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025100305301280000_13.5.e009825.8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02511"},{"key":"2025100305301280000_13.5.e009825.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"2025100305301280000_13.5.e009825.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"2025100305301280000_13.5.e009825.11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"2025100305301280000_13.5.e009825.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1"},{"key":"2025100305301280000_13.5.e009825.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100305301280000_13.5.e009825.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2025100305301280000_13.5.e009825.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq6990"},{"key":"2025100305301280000_13.5.e009825.16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2458"},{"key":"2025100305301280000_13.5.e009825.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2025100305301280000_13.5.e009825.18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2293","article-title":"Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression","volume":"11","author":"Mardiana","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100305301280000_13.5.e009825.19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk1900","article-title":"TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025100305301280000_13.5.e009825.20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1175"},{"key":"2025100305301280000_13.5.e009825.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09489-1","article-title":"Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy","volume":"22","author":"An","year":"2022","journal-title":"BMC Cancer"},{"key":"2025100305301280000_13.5.e009825.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014"},{"key":"2025100305301280000_13.5.e009825.23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190580","article-title":"The human fetal thymus generates invariant effector \u03b3\u03b4 T cells","volume":"217","author":"Tieppo","year":"2020","journal-title":"J Exp Med"},{"key":"2025100305301280000_13.5.e009825.24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clbc.2017.01.007","article-title":"Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers","volume":"17","author":"Panaccione","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"2025100305301280000_13.5.e009825.25","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/cas.14331","article-title":"Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway","volume":"111","author":"Ni","year":"2020","journal-title":"Cancer Sci"},{"key":"2025100305301280000_13.5.e009825.26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0884"},{"key":"2025100305301280000_13.5.e009825.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0068-6"},{"key":"2025100305301280000_13.5.e009825.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.01.051"},{"key":"2025100305301280000_13.5.e009825.29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/lio2.829","article-title":"A novel MPZL2 c.68delC variant is associated with progressive hearing loss in Chinese population and literature review","volume":"7","author":"Wang","year":"2022","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"2025100305301280000_13.5.e009825.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100989","article-title":"Preparation of mouse pancreatic tumor for single-cell RNA sequencing and analysis of the data","volume":"2","author":"Surumbayeva","year":"2021","journal-title":"STAR Protoc"},{"key":"2025100305301280000_13.5.e009825.31","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ymthe.2021.04.038","article-title":"Composite CD79A\/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival","volume":"29","author":"Julamanee","year":"2021","journal-title":"Mol Ther"},{"key":"2025100305301280000_13.5.e009825.32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0160"},{"key":"2025100305301280000_13.5.e009825.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686725"},{"key":"2025100305301280000_13.5.e009825.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-366419"},{"key":"2025100305301280000_13.5.e009825.35","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of CAR-T cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci Immunol"},{"key":"2025100305301280000_13.5.e009825.36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0159"},{"key":"2025100305301280000_13.5.e009825.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1170"},{"key":"2025100305301280000_13.5.e009825.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00704-3"},{"key":"2025100305301280000_13.5.e009825.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23792-8","article-title":"CD45 pre-exclusion from the tips of T cell microvilli prior to antigen recognition","volume":"12","author":"Jung","year":"2021","journal-title":"Nat Commun"},{"key":"2025100305301280000_13.5.e009825.40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"2025100305301280000_13.5.e009825.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100305301280000_13.5.e009825.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y"},{"key":"2025100305301280000_13.5.e009825.43","first-page":"542","article-title":"Monocytopenia; Induction by Vinorelbine, Cisplatin and Doxorubicin in Breast, Non-Small Cell Lung and Cervix Cancer Patients","volume":"10","author":"Nazir","year":"2016","journal-title":"Int J Health Sci (Qassim)"},{"key":"2025100305301280000_13.5.e009825.44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3353","article-title":"B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?","volume":"14","author":"Chen","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100305301280000_13.5.e009825.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017764"},{"key":"2025100305301280000_13.5.e009825.46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy134"},{"key":"2025100305301280000_13.5.e009825.47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283309"},{"key":"2025100305301280000_13.5.e009825.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2083"},{"key":"2025100305301280000_13.5.e009825.49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0163"},{"key":"2025100305301280000_13.5.e009825.50","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-01952-w","article-title":"Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cancer"},{"key":"2025100305301280000_13.5.e009825.51","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-45750-w","article-title":"Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat Commun"},{"key":"2025100305301280000_13.5.e009825.52","doi-asserted-by":"crossref","unstructured":"Wang H , Wu Z , Cui D , et al . Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice. Sci Transl Med 2025;17. doi:10.1126\/scitranslmed.adl6432","DOI":"10.1126\/scitranslmed.adl6432"},{"key":"2025100305301280000_13.5.e009825.53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/neuonc\/noae226","article-title":"EVA1-antibody drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells","volume":"27","author":"Hou","year":"2025","journal-title":"Neuro Oncol"},{"key":"2025100305301280000_13.5.e009825.54","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s43018-022-00383-0","article-title":"Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors","volume":"3","author":"Zhang","year":"2022","journal-title":"Nat Cancer"},{"key":"2025100305301280000_13.5.e009825.55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1064339","article-title":"Enrichment of T-cell proliferation and memory gene signatures of CD79A\/CD40 costimulatory domain potentiates CD19CAR-T cell functions","volume":"13","author":"Ung","year":"2022","journal-title":"Front Immunol"},{"key":"2025100305301280000_13.5.e009825.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.021"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:30:22Z","timestamp":1759494622000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,7]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jitc-2024-009825"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009825","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}